Abstract Library

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4613 Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,

#4492 Utility of NETest 2.0 as a biomarker for neuroendocrine tumours: The Swiss experience – Real-world data

Introduction: The NETest 2.0 is a PCR assay of circulating mRNA, scored 0-100. It has been developed as a biomarker to diagnose neuroendocrine neoplasia (NEN) and to provide tumour prognostic information.

Conference:

Presenting Author: Chirindel A

Authors: Chirindel A, Wild D, Voegeli M, de Dosso S, Siebenhüner A,

Keywords: NETest, tumour biomarker, NEN, disease presence, disease progression,

#3678 Complete remission of Necrolytic Migratory Erythema related to glucagonoma under octreotide therapy

Introduction: Glucagonomas are rare neuroendocrine tumors (NETs), generally diagnosed with locoregional involvement; it has heterogeneous survival with therapeutic approaches ranging from the use of somatostatin analogues, and cytoreductive surgery to PRRT.

Conference:

Presenting Author:

Authors: González Devia D, Rozo-Paz G, Chalela-Mantilla J, Aguirre Matallana D, Arias Amézquita F,

Keywords: Glucagonoma, Migratory necrolytic erythema, Octreotide, Overall survival, Neuroendocrine tumor,

#3528 Computerized tomography (CT)-based hepatic radiomics phenotypes associate with response to anti-angiogenics in neuroendocrine tumors (NETs): A subanalysis from the phase II TALENT clinical trial

Introduction: The phase II TALENT clinical trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, the role of radiomic predictive biomarkers of response to antiangiogenic drugs remain unknown.

Conference:

Presenting Author: Garcia Alvarez A

Authors: Garcia Alvarez A, Hernando J, Ligero M, Delgado E, Ibrahim T,

Keywords: Lenvatinib, Radiomics,